Raymond James & Associates grew its holdings in Lantheus Holdings Inc (NASDAQ:LNTH) by 43.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,561 shares of the medical equipment provider’s stock after acquiring an additional 4,721 shares during the period. Raymond James & Associates’ holdings in Lantheus were worth $226,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Globeflex Capital L P raised its position in Lantheus by 3.1% in the second quarter. Globeflex Capital L P now owns 126,100 shares of the medical equipment provider’s stock worth $1,835,000 after acquiring an additional 3,800 shares during the period. First Trust Advisors LP raised its position in Lantheus by 18.0% in the second quarter. First Trust Advisors LP now owns 34,273 shares of the medical equipment provider’s stock worth $499,000 after acquiring an additional 5,221 shares during the period. Legal & General Group Plc raised its position in Lantheus by 10.0% in the second quarter. Legal & General Group Plc now owns 61,551 shares of the medical equipment provider’s stock worth $898,000 after acquiring an additional 5,605 shares during the period. NumerixS Investment Technologies Inc increased its stake in shares of Lantheus by 1,000.0% in the second quarter. NumerixS Investment Technologies Inc now owns 7,700 shares of the medical equipment provider’s stock worth $113,000 after purchasing an additional 7,000 shares in the last quarter. Finally, Itau Unibanco Holding S.A. purchased a new stake in shares of Lantheus in the second quarter worth $104,000. Institutional investors and hedge funds own 92.62% of the company’s stock.
A number of brokerages have recently issued reports on LNTH. BidaskClub raised shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Wednesday, September 5th. Wells Fargo & Co reduced their price objective on shares of Lantheus from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Thursday, August 2nd. Credit Suisse Group reduced their price objective on shares of Lantheus from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Thursday, August 2nd. ValuEngine raised shares of Lantheus from a “sell” rating to a “hold” rating in a research note on Thursday, August 2nd. Finally, Zacks Investment Research cut shares of Lantheus from a “hold” rating to a “sell” rating in a research note on Saturday, August 4th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $23.75.
Shares of NASDAQ LNTH opened at $15.16 on Friday. The company has a debt-to-equity ratio of 5.94, a current ratio of 3.86 and a quick ratio of 3.14. The firm has a market capitalization of $486.03 million, a PE ratio of 14.67, a PEG ratio of 2.92 and a beta of 1.32. Lantheus Holdings Inc has a 1 year low of $12.59 and a 1 year high of $24.45.
Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Tuesday, October 30th. The medical equipment provider reported $0.24 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.18 by $0.06. The firm had revenue of $88.90 million during the quarter, compared to analysts’ expectations of $83.53 million. Lantheus had a net margin of 36.75% and a return on equity of 97.39%. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.24 earnings per share. As a group, research analysts predict that Lantheus Holdings Inc will post 0.87 earnings per share for the current fiscal year.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.
Recommended Story: Buyback
Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings Inc (NASDAQ:LNTH).
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.